Our Statements

The opioid crisis is a tremendously complex public health issue that demands a public health response. This page will share Janssen statements about important aspects of this issue and provide accurate data to correct misinformation and unsubstantiated claims made against us in lawsuits related to these medicines.


  • Excerpt from Johnson & Johnson Press Release on Ohio Trial Settlement Agreement

    Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial

    Company acted responsibly with its products and the settlement is not an admission of liability

    $10 million settlement payment and additional commitments address all claims of the two counties

    Company remains open to negotiating a viable, broader resolution to outstanding cases


    NEW BRUNSWICK, NJ – October 1, 2019: Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties’ claims with no admission of liability and removes the Company from the federal trial scheduled to begin October 21, 2019. As part of the agreement, the Company will make a combined $10 million settlement payment to the counties.

    The settlement allows the Company to avoid the resource demands and uncertainty of a trial as it continues to seek meaningful progress in addressing the nation’s opioid crisis. The Company recognizes the opioid crisis is a complex public health challenge and is working collaboratively to help communities and people in need.

    Read the full press release by clicking here.


  • Excerpt from Johnson & Johnson Press Release on Oklahoma Lawsuit Judgment

    Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma

    Company did not cause opioid crisis; neither facts nor law support this outcome

    Company confident it has strong grounds for appeal


    NEW BRUNSWICK, NJ – August 26, 2019: Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies today announced they will appeal the $572 million civil judgment entered in Cleveland County District Court in the State of Oklahoma’s lawsuit against opioid manufacturers. The Company is confident it has strong grounds to appeal this decision.

    The judgment disregards the Company’s compliance with federal and state laws, the unique role its medicines play in the lives of the people who need them, its responsible marketing practices and that since launch, DURAGESIC®, NUCYNTA® and NUCYNTA® ER have accounted for less than one percent of total opioid prescriptions in Oklahoma as well as the United States.

    “Janssen did not cause the opioid crisis in Oklahoma, and neither the facts nor the law support this outcome,” said Michael Ullmann, Executive Vice President, General Counsel, Johnson & Johnson. “We recognize the opioid crisis is a tremendously complex public health issue and we have deep sympathy for everyone affected. We are working with partners to find ways to help those in need.”

    Read the full press release by clicking here.


  • Statement from John Sparks, Oklahoma counsel for Janssen Pharmaceuticals, Inc. and Johnson & Johnson, on Filing of Findings of Fact and Conclusions of Law in Oklahoma Trial

    We agree opioid abuse is a significant public health problem in Oklahoma, but the facts and the law in this case warrant a judicial decision rejecting the State’s public nuisance claim. Not once did the State identify a single Oklahoma doctor who was misled by a single Janssen statement, nor did it prove that Janssen misleadingly marketed opioids or caused any harm in Oklahoma. The State’s attempt to resolve this tremendously complex social problem with an unprecedented expansion of public nuisance law is misguided and legally unsustainable


  • Statement from Janssen Pharmaceuticals, Inc. on Oklahoma Trial Closing Arguments

    We recognize that opioid abuse and addiction in Oklahoma and across the United States is a complex and serious problem, and it requires all of us – companies, scientists, frontline health care professionals, regulators and policymakers – to work together. Public health issues require public health solutions, and we are committed to participating in the ongoing efforts.

    In this litigation, the evidence showed that our company responsibly marketed and promoted our prescription opioid medicines, appropriately following the law and regulatory process. We did what a responsible company should do.


  • Statement from John Sparks, Oklahoma counsel for Janssen Pharmaceuticals, Inc. and Johnson & Johnson, on Oklahoma Trial Closing Arguments

    Throughout trial, our team repeatedly laid waste to the State’s case which it built on misstatements and distortions. The facts are that Janssen appropriately provided essential pain treatment options to Oklahomans while balancing the inherent risks associated with these medicines.

    The evidence presented by the State does not support its sweeping allegations. Instead, they unfairly and improperly continue to pursue their unsustainable case – with broad ramifications for industry – by asking the court to legislate and arbitrate this incredibly complex public health problem.

    Janssen and Johnson & Johnson will continue to work towards meaningful solutions, outside of the courtroom. We respectfully await the judge’s decision.


  • Counsel for Janssen Pharmaceuticals, Inc. and Johnson & Johnson Files Motion for Judgment

    We recognize that the opioid abuse crisis is a complex problem, and we are committed to being part of the ongoing dialogue to find ways to address this crisis. Despite the complexity of this problem, the State of Oklahoma is attempting to hold Janssen and Johnson & Johnson liable for billions of dollars in damages – all without offering evidence that shows our companies were the cause of Oklahoma’s opioid crisis.

    After five weeks of testimony, the State of Oklahoma has officially rested its case. On July 3, Janssen and Johnson & Johnson filed a motion for judgement that outlines our view that the State did not present sufficient evidence to support its claims.

    The motion is available here.


  • Statement from John Sparks, Oklahoma counsel for Janssen Pharmaceuticals, Inc. and Johnson & Johnson, on Motion for Judgment

    Despite the stated complexity of this problem, the State is attempting to hold Janssen and Johnson & Johnson liable for damages without offering any evidence that the companies were the cause of Oklahoma’s opioid crisis. The State’s case disregards federal laws and regulations concerning prescription medicines, and ignores established legal precedent and the separation of powers doctrine, threatening to thrust the Court and the parties into uncharted legal waters long after the conclusion of this case. Now that the State has formally rested its case, we have filed a motion that respectfully requests the Court find in favor of defendants because, as detailed fully in the motion, the State does not have sufficient evidence to prove its claims.


  • Statement from Janssen Pharmaceuticals, Inc. on the Opioid Addiction Public Health Issue

    Our actions in the marketing and promotion of these important prescription pain medications were appropriate and responsible. The FDA-approved labels for these prescription pain medications provide clear information about their risks and benefits. The allegations made against our company are baseless and unsubstantiated. In fact, since 2008, our opioid medications have accounted for less than one percent of the U.S. market for this class of medications (including generics).

    Opioid abuse and addiction are serious public health issues. We are committed to being part of the ongoing dialogue and to doing our part to find ways to address this crisis.


  • Statement from Janssen Pharmaceuticals, Inc. on Recent Teva Announcement in Oklahoma

    We acted responsibly in providing FDA-approved pain medications, and we are ready for trial. We disagree with the State’s overly expansive theories of public nuisance law, which should not apply in this situation. At the same time, as with all litigation, if an appropriate resolution is possible that avoids the expense and uncertainty of a trial, we are always open to that option.


  • Statement from John Sparks, Oklahoma counsel for Janssen Pharmaceuticals, Inc. and Johnson & Johnson, on Noramco and Tasmanian Alkaloids

    The State ignores basic facts. Johnson & Johnson did not manufacture, sell, or market the FDA-approved medicines made by other companies that used Noramco APIs. The State also ignores that the production of raw materials and active pharmaceutical ingredients are tightly regulated by the FDA and DEA, both of which approved Noramco’s output.


  • Statement from John Sparks, Oklahoma counsel for Janssen Pharmaceuticals, Inc. and Johnson & Johnson, on Application of Public Nuisance Law

    Oklahoma for more than a century has limited public nuisance to disputes involving property or public spaces—for example, to remedy an intrusion from an overgrown hedge.  The State ignores this well-established law and now argues that public nuisance allows them to compel any party allegedly contributing in any measure to a social problem to fund all programs that state administrators dream up to address it.  This is not and should not be the law.  It threatens every company and industry doing business in the State of Oklahoma.


Disclaimer:

*Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, Inc. are publicly presenting on this website documents provided that have been disclosed as part of ongoing discovery in this litigation. Documents shared here are not confidential or have been released by the court as part of ongoing litigation. This website will be periodically updated.

Back to top